You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel, Nanostructured, Metal-organic Frameworks-Based Product Loss Prevention Technology in the Oil and Natural Gas Sector
SBC: FRAMERGY INC Topic: 17NCER2CTo reach the end user, oil and gas production at the wellhead must be transmitted through the country and distributed to a wide range of customers. This logistical system requires natural gas gathering lines, processing facilities, product storage tanks and lots of other equipment. What results is air pollution caused by industry losses during these operations and the use of continuous or intermit ...
SBIR Phase I 2018 Environmental Protection Agency -
A High-Throughput, Multi-Omic Assay of Tumor Biomarkers from Single-Cells
SBC: ISOPLEXIS CORPORATION Topic: 172SUMMARY Although solid tumors oftentimes arise from the uninhibited growth of a single aberrant cellthe population of cells within a tumor are genetically and molecularly heterogenousThis makes it very difficult to evaluate a therapy s efficacy when using bulk population measurementsFurthermorerecent research has implicated microRNAsmiRNAsas drivers of progression and malignancy in many tumor type ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Double Balloon Catheter for the Treatment of Intussusception in Children
SBC: SEALCATH LLC Topic: NICHDPROJECT SUMMARY ABSTRACT During Phase ISealCathLLC will test the feasibility of its innovative Double Balloon CatheterDBCwhich the United States Utility Patent application was approved on Augustand is in the process of issuing a patentLicensed from the Medical University of South Carolinathis DBC will be commercialized in Phase III as the trademarked nameCephus Catheterwith targeted end users bein ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Reliable Switched Angle Spinning (SAS) Probe with Gradients (PFG) for Proteins in Solid-State NMR
SBC: DOTY SCIENTIFIC, INC. Topic: 400A Reliable Switched Angle SpinningSASProbe with GradientsPFGfor Proteins in Solid State NMR AbstractSolid state NMRssNMRbiotechnology is emerging as an alternative method of choice for highresolution structure determination for integral membrane proteinsIMPsssNMR provides a unique platform to investigate protein dynamicsand functional studies of wide range of biomolecules in their supramolecular a ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Combined High-Throughput Single-Cell Transcriptomic and Secretomic Assay for Neurodegenerative Disease Biomarker Discovery
SBC: ISOPLEXIS CORPORATION Topic: 105In this Phase I application IsoPlexis proposes to deliver a novel method for targeted profiling of both the transcriptome and secretome from an array ofsingle central and peripheral immune cellsSpecificallywe will deliver a single cellmRNA and secreted protein capture assay with proven sensitivity for detecting the most important predictive biomarkers for neurodegenerative diseasesThere is growing ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance
SBC: ISOPLEXIS CORPORATION Topic: 102Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure
SBC: ToleRaM NanoTech LLC Topic: NIBIBABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Construction and testing of a rabbit cornea-equivalent for evaluation of chemical injury in vitro
SBC: TISSUE TESTING TECHNOLOGIES LLC Topic: NIEHSABSTRACTWe propose combination of the rabbit cornea endothelial and epithelial cells with bioengineered scaffolds in cell culture well insertsThis technology could significantly reduce the use of rabbits for the Draize rabbit eye irritation assayThe barrier to commercialization is the lack of an effective method for storingbankingof living bioengineered cornea equivalentsWe will combine cell expan ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health